Analysis of a gene panel for targeted sequencing of colorectal cancer samples

Klaus Højgaard Jensen; Jose M.G. Izarzugaza; Agnieszka Sierakowska Juncker; Rasmus Borup Hansen; Torben Frøstrup Hansen; Pascal Timshel; Thorarinn Blondal; Thomas Skøt Jensen; Eske Rygaard-Hjalsted; Peter Mouritzen; Michael Thorsen; Rasmus Wernersson; Henrik Bjørn Nielsen; Anders Jakobsen; Søren Brunak; Flemming Brandt Sørensen

doi:10.18632/oncotarget.24138

Analysis of a gene panel for targeted sequencing of colorectal cancer samples

Klaus Højgaard Jensen, Jose M.G. Izarzugaza, Agnieszka Sierakowska Juncker, Rasmus Borup Hansen, Torben Frøstrup Hansen, Pascal Timshel, Thorarinn Blondal, Thomas Skøt Jensen, Eske Rygaard-Hjalsted, Peter Mouritzen, Michael Thorsen, Rasmus Wernersson, Henrik Bjørn Nielsen, Anders Jakobsen, Søren Brunak, Flemming Brandt Sørensen

Disease Systems Biology Program

3 Citations (Scopus)

Abstract

Colorectal cancer (CRC) is a leading cause of death worldwide. Surgical intervention is a successful treatment for stage I patients, whereas other more advanced cases may require adjuvant chemotherapy. The selection of effective adjuvant treatments remains, however, challenging. Accurate patient stratification is necessary for the identification of the subset of patients likely responding to treatment, while sparing others from pernicious treatment. Targeted sequencing approaches may help in this regard, enabling rapid genetic investigation, and at the same time easily applicable in routine diagnosis. We propose a set of guidelines for the identification, including variant calling and filtering, of somatic mutations driving tumorigenesis in the absence of matched healthy tissue. We also discuss the inclusion criteria for the generation of our gene panel. Furthermore, we evaluate the prognostic impact of individual genes, using Cox regression models in the context of overall survival and disease-free survival. These analyses confirmed the role of commonly used biomarkers, and shed light on controversial genes such asCYP2C8. Applying those guidelines, we created a novel gene panel to investigate the onset and progression of CRC in 273 patients. Our comprehensive biomarker set includes 266 genes that may play a role in the progression through the different stages of the disease. Tracing the developmental state of the tumour, and its resistances, is instrumental in patient stratification and reliable decision making in precision clinical practice.

Original language	English
Journal	OncoTarget
Volume	9
Issue number	10
Pages (from-to)	9043-9060
Number of pages	18
ISSN	1949-2553
DOIs	https://doi.org/10.18632/oncotarget.24138
Publication status	Published - 2018

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.18632/oncotarget.24138

index.php?journal=oncotarget&page=article&op=download&path%5B%5D=24138&path%5B%5D=75877Final published version, 1.19 MBLicence: CC BY

Cite this

Jensen, K. H., Izarzugaza, J. M. G., Juncker, A. S., Hansen, R. B., Hansen, T. F., Timshel, P., Blondal, T., Jensen, T. S., Rygaard-Hjalsted, E., Mouritzen, P., Thorsen, M., Wernersson, R., Nielsen, H. B., Jakobsen, A., Brunak, S., & Sørensen, F. B. (2018). Analysis of a gene panel for targeted sequencing of colorectal cancer samples. OncoTarget, 9(10), 9043-9060. https://doi.org/10.18632/oncotarget.24138

Jensen, KH, Izarzugaza, JMG, Juncker, AS, Hansen, RB, Hansen, TF, Timshel, P, Blondal, T, Jensen, TS, Rygaard-Hjalsted, E, Mouritzen, P, Thorsen, M, Wernersson, R, Nielsen, HB, Jakobsen, A, Brunak, S & Sørensen, FB 2018, 'Analysis of a gene panel for targeted sequencing of colorectal cancer samples', OncoTarget, vol. 9, no. 10, pp. 9043-9060. https://doi.org/10.18632/oncotarget.24138

@article{d80ec5666a094680a67036cf8003706f,

title = "Analysis of a gene panel for targeted sequencing of colorectal cancer samples",

abstract = "Colorectal cancer (CRC) is a leading cause of death worldwide. Surgical intervention is a successful treatment for stage I patients, whereas other more advanced cases may require adjuvant chemotherapy. The selection of effective adjuvant treatments remains, however, challenging. Accurate patient stratification is necessary for the identification of the subset of patients likely responding to treatment, while sparing others from pernicious treatment. Targeted sequencing approaches may help in this regard, enabling rapid genetic investigation, and at the same time easily applicable in routine diagnosis. We propose a set of guidelines for the identification, including variant calling and filtering, of somatic mutations driving tumorigenesis in the absence of matched healthy tissue. We also discuss the inclusion criteria for the generation of our gene panel. Furthermore, we evaluate the prognostic impact of individual genes, using Cox regression models in the context of overall survival and disease-free survival. These analyses confirmed the role of commonly used biomarkers, and shed light on controversial genes such asCYP2C8. Applying those guidelines, we created a novel gene panel to investigate the onset and progression of CRC in 273 patients. Our comprehensive biomarker set includes 266 genes that may play a role in the progression through the different stages of the disease. Tracing the developmental state of the tumour, and its resistances, is instrumental in patient stratification and reliable decision making in precision clinical practice.",

author = "Jensen, {Klaus H{\o}jgaard} and Izarzugaza, {Jose M.G.} and Juncker, {Agnieszka Sierakowska} and Hansen, {Rasmus Borup} and Hansen, {Torben Fr{\o}strup} and Pascal Timshel and Thorarinn Blondal and Jensen, {Thomas Sk{\o}t} and Eske Rygaard-Hjalsted and Peter Mouritzen and Michael Thorsen and Rasmus Wernersson and Nielsen, {Henrik Bj{\o}rn} and Anders Jakobsen and S{\o}ren Brunak and S{\o}rensen, {Flemming Brandt}",

year = "2018",

doi = "10.18632/oncotarget.24138",

language = "English",

volume = "9",

pages = "9043--9060",

journal = "OncoTarget",

issn = "1949-2553",

publisher = "Impact Journals LLC",

number = "10",

}

TY - JOUR

T1 - Analysis of a gene panel for targeted sequencing of colorectal cancer samples

AU - Jensen, Klaus Højgaard

AU - Izarzugaza, Jose M.G.

AU - Juncker, Agnieszka Sierakowska

AU - Hansen, Rasmus Borup

AU - Hansen, Torben Frøstrup

AU - Timshel, Pascal

AU - Blondal, Thorarinn

AU - Jensen, Thomas Skøt

AU - Rygaard-Hjalsted, Eske

AU - Mouritzen, Peter

AU - Thorsen, Michael

AU - Wernersson, Rasmus

AU - Nielsen, Henrik Bjørn

AU - Jakobsen, Anders

AU - Brunak, Søren

AU - Sørensen, Flemming Brandt

PY - 2018

Y1 - 2018

N2 - Colorectal cancer (CRC) is a leading cause of death worldwide. Surgical intervention is a successful treatment for stage I patients, whereas other more advanced cases may require adjuvant chemotherapy. The selection of effective adjuvant treatments remains, however, challenging. Accurate patient stratification is necessary for the identification of the subset of patients likely responding to treatment, while sparing others from pernicious treatment. Targeted sequencing approaches may help in this regard, enabling rapid genetic investigation, and at the same time easily applicable in routine diagnosis. We propose a set of guidelines for the identification, including variant calling and filtering, of somatic mutations driving tumorigenesis in the absence of matched healthy tissue. We also discuss the inclusion criteria for the generation of our gene panel. Furthermore, we evaluate the prognostic impact of individual genes, using Cox regression models in the context of overall survival and disease-free survival. These analyses confirmed the role of commonly used biomarkers, and shed light on controversial genes such asCYP2C8. Applying those guidelines, we created a novel gene panel to investigate the onset and progression of CRC in 273 patients. Our comprehensive biomarker set includes 266 genes that may play a role in the progression through the different stages of the disease. Tracing the developmental state of the tumour, and its resistances, is instrumental in patient stratification and reliable decision making in precision clinical practice.

AB - Colorectal cancer (CRC) is a leading cause of death worldwide. Surgical intervention is a successful treatment for stage I patients, whereas other more advanced cases may require adjuvant chemotherapy. The selection of effective adjuvant treatments remains, however, challenging. Accurate patient stratification is necessary for the identification of the subset of patients likely responding to treatment, while sparing others from pernicious treatment. Targeted sequencing approaches may help in this regard, enabling rapid genetic investigation, and at the same time easily applicable in routine diagnosis. We propose a set of guidelines for the identification, including variant calling and filtering, of somatic mutations driving tumorigenesis in the absence of matched healthy tissue. We also discuss the inclusion criteria for the generation of our gene panel. Furthermore, we evaluate the prognostic impact of individual genes, using Cox regression models in the context of overall survival and disease-free survival. These analyses confirmed the role of commonly used biomarkers, and shed light on controversial genes such asCYP2C8. Applying those guidelines, we created a novel gene panel to investigate the onset and progression of CRC in 273 patients. Our comprehensive biomarker set includes 266 genes that may play a role in the progression through the different stages of the disease. Tracing the developmental state of the tumour, and its resistances, is instrumental in patient stratification and reliable decision making in precision clinical practice.

U2 - 10.18632/oncotarget.24138

DO - 10.18632/oncotarget.24138

M3 - Journal article

C2 - 29507673

SN - 1949-2553

VL - 9

SP - 9043

EP - 9060

JO - OncoTarget

JF - OncoTarget

IS - 10

ER -

Analysis of a gene panel for targeted sequencing of colorectal cancer samples

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this